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Objectives: This study investigated the outcomes and management associated 
with stroke prevention treatments in patients with non-valvular atrial fibrilla-
tion (NVAF) in Europe. The primary objective of this analysis was to assess the 
management of patients treated with vitamin K antagonists (VKA). MethOds: 
We conducted an observational retrospective cohort study of patients with NVAF 
in the Longitudinal Patient Database (CEGEDIM) in France, Italy, the UK, Spain and 
Germany. The analysis included patients > = 18 years old with recorded AF diag-
nosis, treated with VKA, and without rheumatic valvular disease or prosthetic 
valves prior to the index date (date of 1stvisit during inclusion period – May 2010 
- April 2012 - , or date for first AF diagnosis, if this falls during this period. Only 
patients with > = 1 year of data were included to ensure adequate data avail-
ability. Using recorded INR measures, we estimated the average time within 
therapeutic range (TTR), INR between 2 and 3 for patients eligible to apply the 
Rosendaal Method. Results: In France 1,110 patients were assessed, in Germany 
1,208, in Italy 1,230, & the UK 2,702. Insufficient data were retrieved in Spain 
(n= 12). INR was measured 9.6 times/year in France, 9.5 times/year in Germany, 
9.8times/year in Italy, and 13.1 times/year in the UK. In France, 48% of the patients 
had TTR > = 70% of their time; in Germany, 44%; in Italy, 46%, and in the UK, 
65%. cOnclusiOns: Treatment outcomes with VKAs, in particular stroke and 
bleeding, depend on maintaining patients’ INR values within recommended 
range. The results show that the majority of patients in France, Germany and 
Italy, & 1/3 of patients in UK did not achieve recommended TTR and therefore 
were at increased risk of stroke or major bleeding. Further research is needed 
to demonstrate the correlation between these estimates and stroke and major 
bleeding rates within countries.
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Objectives: To investigate the prescribing of hypolipidaemic agents with specific 
emphasis on the effect of generic prescribing on HMG-CoA reductase inhibitor (statin) 
costs. MethOds: A retrospective, cross-sectional pharmacoepidemiological study 
was conducted on 2011 medical insurance claims data in South Africa. Results: A 
total of 4805 patients (56.88% males) were prescribed 38373 hypolipidaemic agents. 
The average age of patients was 56.07 (SD= 13.32) years. Statins accounted for 93.85% 
of all prescriptions and 83.44% of cost, followed by fibrates (3.61% of prescribing fre-
quency and 7.72% of cost). Simvastatin was the most frequently prescribed statin 
(accounting for 62.59% of all prescriptions), followed by atorvastatin (17.04%) and 
rosuvastatin (11.68%). Simvastatin was also the active ingredient with the lowest aver-
age cost per product of R46.43. Simvastatin was prescribed under 16, atorvastatin six 
and pravastatin four different trade names. Fluvastatin, lovastatin and rosuvastatin 
only had one trade name under which they were prescribed. Only one cholesterol 
absorption inhibitor drug was prescribed (ezetimibe) accounting for 1.64% of prescrip-
tions. This product had the highest average cost per prescription of R416.37. Other 
hypolipidaemic agents prescribed accounted for only 0.89% and consisted of the com-
bination of ezetimibe and simvastatin, and cholestyramine. The fibrates constituted 
3.61% of prescribing, with most prescriptions for bezafibrate. Dosages for the statins 
were investigated and it was found that the average Prescribed Daily Doses (PDDs) 
were generally lower or in agreement with the Defined Daily Doses (DDDs). The aver-
age PDD of simvastatin was 23.70 (DDD= 30 mg), pravastatin 25.35 mg (DDD= 30 mg), 
lovastatin 26.31 mg (DDD= 45 mg), atorvastatin 20.91 (DDD= 20 mg) and fluvastatin 
57.29 mg (DDD= 60 mg). cOnclusiOns: There are a variety of generic equivalents 
available for the statins on the South African market. It was clear that products with 
more generic equivalents had a lower average cost per prescription compared to the 
innovator products.
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Objectives: Calcium channel blockers are drugs of first choice in the treatment 
of hypertension. The aim of this study was to analyze the consumption of calcium 
channel blockers in Serbia in the period from 2007 to 2011 year. MethOds: The data 
about the use of drugs were taken from the Agency for Drugs and Medical Devices 
of the Serbia. Results: The most frequently used drug from this group with mainly 
vascular effects was amlodipine. During this observed five years the consumption 
of amlodipine is in steadily increased. In 2007. it was 21.25DDD/1000 inh/day, at the 
end of 2011. year the consumption was 72.97DDD/1000 inh/day. On the second place 
in drug consumption in the same group of drugs was nifedipine. Contrary to amlodi-
pine, nifedipine recorded a decline in consumption. From the calcium channel 
blockers with direct cardiac effects the most frequently used drugs were verapamil 
and diltiazem. The consumption of verapamil in the observed years was uneven. At 
the and of 2011. consumption of this drug was reduced by 50%. The consumption 
of diltiazem in observed five years is in constantly decreasing. cOnclusiOns: In 
Serbia, in the observed period the consumption of calcium channel blockers been 
uneven. In 2010 and 2011 the consumption of calcium channel blockers marks a 
positive trend. This research was supported by Provincial Secretariat for Science 
and Technological Development, Autonomous Province of Vojvodina project No 
114-451-2458/2011 and by Ministry of Science, Republic of Serbia, project no 41012.
have no VTE diagnosis in the 6 months prior to IH. Parenteral and oral anticoagu-
lants used during IH were identified. Multivariate logistic regression was used to 
examine factors associated with anticoagulant use. Results: A total of 957 VTE 
patients were eligible for the study. Mean age was 62.8 years, and 45.1% were male. 
Mean length of stay was 8.7 days. During index hospitalization, 45.4% patients 
were treated with parenteral anticoagulants (PA) and warfarin, 24.6% with warfa-
rin only, and 13.6% with PA only. Among patients treated with PA, low molecular 
weight heparin accounted for 93.4%. Chemotherapy (OR= 2.24), respiratory disease 
(OR= 1.44), and pulmonary embolism (PE) vs deep vein thrombosis (DVT) (OR= 1.42) 
were significantly associated with PA use, while prior stroke (OR= 0.43) and renal 
disease (OR= 0.58) were associated with less likelihood of PA use. DVT plus PE 
vs DVT (OR= 3.87), obesity (OR= 2.57), chemotherapy (OR= 2.23), and PE vs DVT 
(OR= 2.19) were significantly associated with warfarin use, while bleeding history 
(OR= 0.41), diabetes (OR= 0.64), and heart disease (OR= 0.67) were associated with 
less likelihood of warfarin use. cOnclusiOns: Less than half of VTE patients dur-
ing hospitalization were prescribed PA and warfarin, 25% warfarin only, and 14% 
PA only. Clinical factors including VTE type, stroke and bleeding history, comorbid 
respiratory disease, diabetes, heart disease, obesity, and chemotherapy were asso-
ciated with anticoagulant use. Further research needs to examine characteristics 
and health outcomes of patients who did not receive parenteral anticoagulants 
during hospitalization.
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Objectives: The REACT AF study investigated the outcomes and management 
associated with stroke prevention treatments in patients with non-valvular atrial 
fibrillation (NVAF) in Europe. This analysis assessed 1) the use of oral anticoagulation 
drugs (OACs) and 2) whether current practice is consistent with the 2012 European 
Society of Cardiology (ESC) recommendations. MethOds: We conducted an obser-
vational retrospective cohort study of patients with NVAF in the Longitudinal Patient 
Database (CEGEDIM) in France, Italy, UK, Spain and Germany. The analysis included 
patients > = 18 years old, with AF diagnosis, and without rheumatic valvular disease 
or prosthetic valves. Patients had to be in the database for ≥ 1 year before date of 1st 
visit (index date) during the inclusion period (May 2010-April 2012). We calculated 
patients’ CHA2DS2-VASc score at index date for untreated patients and at the time of 
the current OAC initiation for treated patients. We evaluated patients’ requirement 
for stroke prevention therapy based on the 2012 ESC recommendations and calcu-
lated the percentage of patients for whom treatment initiation and OAC use were 
consistent with recommendations. Results: In France 53% of the OAC patients 
(total= 16,329) were treated consistently with the 2012 ESC recommendations (treat-
ment requirement and choice of OAC); 46% in Germany (total= 13,468), 58% in Spain 
(total= 12,357); 39% in Italy (total= 22,447); and 36% in the UK (total= 19,956). The per-
centage of patients (CHA2DS2-Vasc> 1, if not alone due to female gender) not receiv-
ing the required treatment (either not treated or treated with a non-recommended 
OAC) was 36% in France; 48% in Germany; 34% in Spain; 52% in Italy; and 48% in 
the UK. cOnclusiOns: The study findings indicate there is a discrepancy between 
current practice regarding OAC prescribing and the 2012 ESC recommendations. 
Special attention must be given to time of treatment initiation and choice of OAC 
to correctly follow ESC recommendations.
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Objectives: This study investigated the outcomes and management associated 
with stroke prevention treatments in patients with non-valvular atrial fibrillation 
(NVAF) in Europe. This analysis estimated persistence and adherence to treatment 
with VKA. MethOds: We conducted an observational retrospective cohort study 
of patients with NVAF in the Longitudinal Patient Database (CEGEDIM) in France, Italy, 
the UK, Spain and Germany. The analysis included patients > = 18 years old, with 
AF diagnosis, treated with VKA and without rheumatic valvular disease or pros-
thetic valves. Patients had to be in the database for > = 1 year before date of 1stvisit 
during inclusion period (May 2010/April 2012). We estimated persistence (time to 
VKA discontinuation) as the time from first prescription to last prescription before 
discontinuation, defining discontinuation as switch or absence of renewal within 
3 months, using the Kaplan-Meier method. We measured adherence to treatment 
by the Medication Possession Ratio (MPR) during the inclusion period. Results: 
Median time to treatment discontinuation was 0.78 year in Germany (n= 6,386), 1.00 
year in Italy (n= 8,774), 1.34 years in France (n= 9,184), 1.99 years in Spain (n= 7,526), 
and 1.92 years in the UK (n= 7,731). Persistence at 5 years was 12% in Germany, 20% 
in Italy, 24% in France, 26% in Spain, and 25% in the UK. Concerning adherence the 
mean MPR was 0.54 in Spain, 0.56 in Italy, 0.57 in France, and 0.59 in Germany. There 
was insufficient data to estimate adherence in the UK. cOnclusiOns: MPR > = 0.80 
is used to define good adherence. The results show adherence to treatment with 
VKA is low in the countries studied. Results were consistent across countries, which 
suggest that low adherence is not country specific. Low adherence to treatment with 
VKA can affect the maintenance of patients within recommended range of INR, and 
therefore may increase the risk of stroke.
